Patients with EGFR-mutant NSCLC or females, who were identified as high-risk for DM, presented no decrease in the percentage of DM as initial recurrence in CCRT+D compared with the CCRT cohort (75% vs 60%). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.